603456 九洲药业
2024/09 - 九个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入3,965,261-13.36%5,523,4185,445,1054,063,1822,647,284
减:营业总成本3,190,787-6.77%4,275,8354,281,4543,332,4362,243,734
    其中:营业成本2,587,368-6.85%3,443,4933,557,8162,709,0511,654,390
               财务费用(49,713)-12.09%(75,635)(86,168)37,19591,661
               资产减值损失(38,630)-26.65%(78,204)(59,326)(50,811)(22,167)
公允价值变动收益------(35,222)(1,390)35,973
投资收益(4,630)-79.62%(19,364)2,07061,0684,987
    其中:对联营企业和合营企业的投资收益(8,289)61.88%(7,756)591,1992,469
营业利润747,100-31.20%1,175,7711,107,912753,635456,149
利润总额746,710-31.37%1,180,6421,103,822744,740449,902
减:所得税费用113,857-7.89%149,270182,848110,58970,015
净利润632,852-34.38%1,031,372920,973634,151379,888
减:非控股权益1,976-183.80%(1,884)(197)250(697)
股东净利润630,877-34.74%1,033,256921,170633,901380,585

市场价值指针
每股收益 (元) *0.700-35.78%1.1601.1100.7700.470
每股派息 (元) *----0.5000.4000.2500.200
每股净资产 (元) *9.5051.79%9.4076.3495.4973.829
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容